Jazz Pharmaceuticals PLC (JAZZ)

The total asset value of Jazz Pharmaceuticals PLC (JAZZ) stood at $ 12,012 Mln as on 31-Dec-24

The share price of Jazz Pharmaceuticals PLC (JAZZ) is $105.37 (NASDAQ) as of 23-Apr-2025 13:37 EDT. Jazz Pharmaceuticals PLC (JAZZ) has given a return of -13.53% in the last 3 years.

Jazz Pharmaceuticals PLC (JAZZ) has a market capitalisation of $ 6,094 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.

The P/E ratio of Jazz Pharmaceuticals PLC (JAZZ) is 11.60 times as on 22-Apr-2025.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Jazz Pharmaceuticals PLC (JAZZ) and enter the required number of quantities and click on buy to purchase the shares of Jazz Pharmaceuticals PLC (JAZZ).

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland. Address: Waterloo Exchange, Dublin, Ireland, D04 E5W7

The CEO & director of Mr. Bruce C. Cozadd. is Jazz Pharmaceuticals PLC (JAZZ), and CFO & Sr. VP is Mr. Bruce C. Cozadd.

There is no promoter pledging in Jazz Pharmaceuticals PLC (JAZZ).

Some of the close peers are:

No, TTM profit after tax of Jazz Pharmaceuticals PLC (JAZZ) was $0 Mln.